4-1BB Ligand/TNFSF9 (Human, Recombinant)

Product Description

4-1BB Ligand/TNFSF9 (Human, Recombinant)
Catalog number: B2010330
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 10 ug
pH: 7.4 upon reconstitution
Supplied as: Lyophilized Powder
Appearance: Powder
Applications: highly pure 4-1BB Ligand/TNFSF9 (Human, Recombinant) expressed in E. coli. This protein acts as a costimulatory member of the TNF family, which are expressed on activated B cells, macrophages, and dendritic cells.
Storage: -20C
Keywords: rHu4-1BBL/TNFSF9; CD137L
Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB ligand in cancer
immunotherapy. Cancer Gene Ther. 2004 Mar;11(3):215-26.

2: Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ,
Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang
H, Pearson AT, Snyder LA, Korman AJ, Tomlins SA, Yegnasubramanian S, Drake CG. A
conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-
cancer target. J Clin Invest. 2020 Mar 2;130(3):1405-1416.

3: Vidard L, Dureuil C, Baudhuin J, Vescovi L, Durand L, Sierra V, Parmantier E.
CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15- and IL-21-Driven NK Cell
Proliferation. J Immunol. 2019 Aug 1;203(3):676-685.

4: Chen S, Fan J, Zhang M, Qin L, Dominguez D, Long A, Wang G, Ma R, Li H, Zhang
Y, Fang D, Sosman J, Zhang B. CD73 expression on effector T cells sustained by
TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nat Commun. 2019
Jan 11;10(1):150.

5: Seo SK, Park HY, Choi JH, Kim WY, Kim YH, Jung HW, Kwon B, Lee HW, Kwon BS.
Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J
Immunol. 2003 Jul 15;171(2):576-83.

6: Laderach D, Wesa A, Galy A. 4-1BB-ligand is regulated on human dendritic
cells and induces the production of IL-12. Cell Immunol. 2003 Nov;226(1):37-44.

7: Cho HR, Kwon B, Yagita H, La S, Lee EA, Kim JE, Akiba H, Kim J, Suh JH, Vinay
DS, Ju SA, Kim BS, Mittler RS, Okumura K, Kwon BS. Blockade of 4-1BB
(CD137)/4-1BB ligand interactions increases allograft survival. Transpl Int.
2004 Aug;17(7):351-61.

8: Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K.
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int
Immunol. 2002 Mar;14(3):275-86.
9: Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL. 4-1BB
ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine. 2006 Jun
5;24(23):4975-86.

Products Related to 4-1BB Ligand/TNFSF9 (Human, Recombinant) : Proteins